Edwards Lifesciences (EW) holder files Rule 144 notice to sell 21,487 shares

Rhea-AI Filing Summary

Edwards Lifesciences Corporation (EW) has a shareholder filing a notice to sell 21,487 shares of its common stock under Rule 144. The shares are to be sold through broker Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $1,831,006 and 580,300,000 common shares stated as outstanding. The seller acquired these shares on 12/08/2025 through an employee stock option exercise, using a broker payment for a cashless exercise on the same date. The person signing the notice represents that they are not aware of any undisclosed material adverse information about Edwards Lifesciences’ current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	21487	1831006.00	580300000	12/08/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/08/2025	Employee Stock Option Exercise	EDWARDS LIFESCIENCES CORPORATION			21487	12/08/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Edwards Lifesciences (EW) disclose in this Form 144?

The notice states that a shareholder plans to sell 21,487 shares of Edwards Lifesciences common stock on the NYSE through Charles Schwab & Co., Inc., with an aggregate market value of $1,831,006.

How many Edwards Lifesciences (EW) shares are involved and what is their value?

The planned sale covers 21,487 common shares of Edwards Lifesciences, with an indicated aggregate market value of $1,831,006.

How were the Edwards Lifesciences (EW) shares being sold under Rule 144 acquired?

The shares were acquired on 12/08/2025 through an employee stock option exercise from Edwards Lifesciences Corporation, using a broker payment for a cashless exercise.

What is the stated number of Edwards Lifesciences (EW) shares outstanding in this notice?

The notice lists 580,300,000 common shares of Edwards Lifesciences as outstanding, providing context for the planned sale amount.

Which broker and exchange are used for the planned Edwards Lifesciences (EW) share sale?

The shares are to be sold through Charles Schwab & Co., Inc., with the NYSE named as the securities exchange.

What representation does the seller make about Edwards Lifesciences (EW) information?

By signing the notice, the seller represents that they do not know of any material adverse information about Edwards Lifesciences’ current or prospective operations that has not been publicly disclosed.